Search clinical trials for: Prevention of Pandemic Influenza

Total 432475 results

Shanghai Institute Of Biological Products

Unknown

A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine

H7N9 Influenza

China
PATH
Institute of Experimental Medicine, Russia; Microgen

Completed

Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Influenza

Russian Federation
AVIR Green Hills Biotechnology AG

Completed

Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults

Influenza, Avian

Russian Federation
Research Institute of Influenza, Russia
World Health Organization; Institute of Experimental Medicine, Russia; Joint...

Unknown

Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine

Vaccine Adverse Reaction
GlaxoSmithKline

Completed

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

Influenza

Spain
Marshfield Clinic Research Foundation
Centers for Disease Control and Prevention

Completed

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

Influenza

United States
GlaxoSmithKline

Completed

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (ZORO)

Influenza, Human

Australia, Taiwan, Korea, Republic of, United States, Belgium, Canada, Germany, South Africa, Spain, United Kingdom, New Zealand, Thailand, India, China, Brazil, Hong Kong, Slovakia, Russian Federation, Denmark, Mexico, Czechia, H... and more
GlaxoSmithKline

Terminated

Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

Influenza

Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Influenza

United States, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old

Influenza

Thailand, Philippines
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
GlaxoSmithKline

Completed

A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.

Influenza

Taiwan
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

Influenza

Japan
GlaxoSmithKline

Completed

Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children

Influenza

Japan
GlaxoSmithKline

Completed

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

Influenza

Germany
GlaxoSmithKline

Completed

Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years

Influenza

Slovakia, Estonia
GlaxoSmithKline

Completed

Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

Influenza

Taiwan, Hong Kong, Thailand, Singapore
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

France, Spain, Germany, Russian Federation, Estonia, Sweden, Netherlands
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
International Centre for Diarrhoeal Disease Research...
Centers for Disease Control and Prevention

Completed

Oseltamivir Randomised Controlled Efficacy Trial

Pneumonia | Influenza | Lower Respiratory Tract Infection | Upper Respiratory Tract Infection | Viral Shedding

Bangladesh
Marshfield Clinic Research Foundation
University of Wisconsin, Madison; Centers for Disease Control and Prevention

Completed

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

Influenza A Virus Infection | Influenza B Virus Infection | Immune Response to Influenza Vaccine

United States
University of Maryland
National Institute of Allergy and Infectious Diseases (NIAID); Centers for...

Completed

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza (EMIT)

Influenza Virus Infection Transmission in Humans

United States
University of Rochester
University of California, Los Angeles

Completed

Evaluation of the School Kids Influenza Prevention Project (SKIPP)

Childhood Influenza Vaccination | School-located Influenza Vaccination

United States
Columbia University
Centers for Disease Control and Prevention

Completed

PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging

Pregnancy

United States
GlaxoSmithKline

Completed

A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection

Influenza, Human

Japan
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

Influenza

Spain
Duke University
Centers for Disease Control and Prevention

Completed

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

Fever

United States
Public Health England
Institute of Child Health

Completed

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™). (LAIV Immuno)

Live Attenuated Influenza Vaccine

United Kingdom
GlaxoSmithKline

Completed

Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom (H1N1 PASS UK)

Influenza

United Kingdom
Abt Associates
Centers for Disease Control and Prevention; Clalit Research Institute

Unknown

Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel (HCP)

Influenza | Respiratory Tract Disease

Israel
Kaiser Permanente
Centers for Disease Control and Prevention

Completed

A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (FluMist)

Healthy | Influenza

United States
GlaxoSmithKline

Completed

Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Influenza

Belgium
UMN Pharma Inc.

Completed

A Study to Evaluate Intramuscular ASP7374

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza | Vaccine

Japan
Jiangsu Province Centers for Disease Control and...
Chengdu Olymvax Biopharmaceuticals Inc.

Completed

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus Influenza
Changchun BCHT Biotechnology Co.
National Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaborators

Completed

A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Influenza

China
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Respiratory Virus Outpatient Study (FLU 002 Plus)

Influenza and Other Novel Respiratory Viruses

United States, Chile, United Kingdom, Spain, Argentina, Australia, Thailand, Peru, Germany, Japan, Greece, Belgium, Denmark, Estonia, Poland
Brigham and Women's Hospital
Department of Health and Human Services; Centers for Medicare and Medicaid... and other collaborators

Completed

Mail Outreach To Increase Vaccination Acceptance Through Engagement (MOTIVATE)

Influenza | Influenza, Human | Human Flu

United States
National Institute of Allergy and Infectious Diseases...

Completed

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Influenza A Virus, H5N1 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

Influenza A Virus, H1N1 Subtype | Novel Swine-Origin

United States
National Institute of Allergy and Infectious Diseases...

Completed

Vaccine for Prevention of Bird Flu

Influenza, Human

United States
GlaxoSmithKline

Completed

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days (NAI113625)

Influenza A Virus, H1N1 Subtype

United States
University of Massachusetts, Worcester
Pfizer; Reliant Medical Group

Completed

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

Influenza | Infections, Pneumococcal

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany

3

Subscribe